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Introduction
Colorectal cancer accounts for one third of cancer-related deaths worldwide and
this trend is still increasing. Although application of comprehensive treatments,
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Purpose: This study aims to screen microRNAs (miRNAs), for an early diagnosis of colorectal cancer, by deep sequencing and evaluation of total miRNAs using clinical samples from a
Chinese patient population.
Methods: Total small RNAs from normal colonic mucosa, colonic adenomas, and colorectal
cancer tissues were prepared for miRNA analysis by deep sequencing. The sequencing data
were then analyzed by bioinformatics for candidate diagnostic miRNAs, which were further
validated for their up- or downregulation status.
Results: Comparison of cancer tissues with normal mucosa identified 99 upregulated and 90
downregulated miRNAs. Comparison of adenomas and normal mucosa found 114 upregulated and 107 downregulated miRNAs. Comparison of cancer and adenoma tissues found 70
upregulated and 27 downregulated miRNAs. Selected up- and downregulated miRNAs were
validated for their expressions in 12 cases of patients with cancer and polyps. Specifically, for the
upregulated miRNAs, miR-18a-5p and miR-21-3p were significantly upregulated in adenomas
and cancer tissues, compared with the normal mucosa; miR-135b-5p, miR-17-5p, miR-182-5p,
miR-200a-5p, and miR-200c-3p were significantly upregulated in cancer tissues compared to the
normal mucosa, but their differential expression was not significant in adenoma tissues when
compared with the normal mucosa. miR-183-5p and miR-96-5p were significantly upregulated in
adenoma tissues when compared with normal mucosa, but these differences were not significant in
cancer tissues when compared to normal mucosa. For the downregulated miRNAs, miR-133a-3p
was significantly downregulated in both adenoma and cancer tissues when compared to normal
mucosa; miR-204-5p, miR-125b-5p, miR-139-5p, miR-100-5p, and miR-30a-5p were significantly downregulated in cancer tissues compared to the normal mucosa, but their differential
expression was not significant in adenoma tissue compared to normal mucosa.
Conclusion: The findings of this study show that a number of miRNAs might be important
in the diagnosis and prognosis of colorectal cancer in Chinese patients using the method of
small RNA deep sequencing. Upregulation of miR-18a-5p and miR-21-3p or downregulation
of miR-133a-3p in adenoma and cancer tissues may serve as an index for early screening of
colorectal cancer. Other miRNAs, such as miR-135b-5p, miR-17-5p, miR-182-5p, miR-200a-5p,
miR-200c-3p, miR-183-5p, and miR-96-5p, which were either up- or downregulated, in cancer
tissues, but not in adenoma tissues, have limited significance in early diagnosis. Further study
is needed to determine a screening index with diagnostic value.
Keywords: colorectal cancer, colorectal adenoma, miRNA, deep sequencing
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including surgery, has achieved a significant improvement
in the 5-year survival rate, the overall estimated death rate is
still ~50%-60%.1 Early diagnosis is thus an effective way to
prolong life of patients with colorectal cancer.
The term micro-RNA (miRNA) refers to a type of small
RNA of length 19–22 nucleotides in vivo. After a series
of reactions, it finally forms an RNA-induced silencing
complex. The miRNA-associated RNA-induced silencing
complex binds to its target messenger RNA (mRNA) at
the 3′-untranslated region, so that it can cleave and degrade
the target mRNA or inhibit further translation of the target
mRNA, leading to a loss of function of the target gene.
miRNA plays an important role in the occurrence and
development of colorectal cancer. miRNA affects many
known oncogenes and antioncogenes and is involved in
the regulation of the signal transduction pathway related
to colorectal cancer. Thus, miRNAs, many of which have
differential expression profiles, may be used to serve as
biological markers for predicting the development of and
prognosis of colorectal cancer.2,3
In recent years, changes of miRNA levels in the human
circulation have gained more attention for their role in
the early diagnosis of colorectal cancer.3–5 Luo et al3 used
TaqMan miRNA slugs in 50 cases of colorectal cancer and
50 cases of adenoma and found nine miRNAs that had differential expression in colorectal cancer when compared to
normal mucosa. They hypothesized that assay of these nine
markers can contribute to the early diagnosis of colorectal
cancer. Ng et al4 assayed 90 known miRNAs in 90 cases
of colorectal cancer, 20 cases of gastric cancer, 20 cases of
inflammatory bowel disease, and 50 healthy people. Their
findings showed that miR-17-3p and miR-92 were increased
in patient blood, and further verification showed that, among
the 180 cases, miR-92 had a distinct increase in patient
blood. In contrast to the report by Ng et al,4 Faltejskova et
al,6 by repeating the research performed by Ng et al4 among
Czech patients, found that the levels of miR-17-3p (P=0.18),
miR-29a (P=0.14), and miR-92a (P=0.60) had no significant
difference in colorectal cancer when compared to a control
group. The differences in findings might have been due to the
distinct sources of samples, including the regional environment distinction of patient samples.
The colorectal cancer screen using miRNAs was claimed
to have sensitivity of 89% and specificity of 70%. Research
reported by Huang et al5 found that using miR-29a and miR92a as biomarkers for early diagnosis had 83% sensitivity
and 84.7% specificity for colorectal cancer diagnosis and
77% sensitivity and 79.7% of specificity for colorectal
polyps.
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Although previous studies showed valuable data on
miRNAs as potential biomarkers in colorectal cancer, results
were still limited and were sometimes contradictory with
each other due to different sources of samples.3–5 Cancerstage-related miRNAs as valuable biomarkers are still lacking. In this study, controlled experiments were performed
on colorectal cancer with its distinct developmental stages,
including colorectal polyps, and on normal mucosa. miRNA
deep sequencing was performed on cancer and precancer
tissues of all stages, to determine simultaneous variations in
the miRNA index for colorectal cancer and colorectal polyps.
This index can be used in further studies to confirm its value
in the early diagnosis of colorectal cancer.

Materials and methods
Clinical specimens
The specimens used for the deep sequencing were from four
typical patients who had undergone surgery or endoscopy
at the National Center of Colorectal Surgery, the Third
Affiliated Hospital of Nanjing University of Traditional
Chinese Medicine. One case was a 52-year-old female, a
patient with colorectal cancer (T2N0M0) who had anterior
resection operation; the cancer tissue and normal mucosa
were taken for study. Another case was a 50-year-old male
with sigmoid cancer with a colon polyp (T3N0M0), who
had received a sigmoidectomy operation for sigmoid cancer
and endoscopic polypectomy for colon adenoma; the cancer,
adenoma, and normal mucosa tissues were taken for study. A
third case was a patient with polyps in the cecum and cancer
of the horizontal colon (T3N1M0); a right hemicolectomy
surgery was performed; his cancer, adenoma, and normal
mucosa tissues were obtained for study. A fourth case had
a polyp of the sigmoid colon; endoscopic mucosal resection was performed and specimens were taken for study. In
total, there were three samples each of cancer, adenoma, and
normal mucosa tissues. All samples were preserved in liquid
nitrogen. The study was approved by the Ethics Committee
of The Third Affiliated Hospital of Nanjing, University of
Traditional Chinese Medicine, and all patients provided
written informed consent.

miRNA deep sequencing
We implemented miRNA deep sequencing with the method
published by Schee et al7 and carried out high-throughput
sequencing on the specimens using the 50 bp single-end
sequencing model on an Illumina HiSeq2500 (Illumina, San
Diego, CA, USA) sequencing platform. Frozen specimens
were used with the Sangong kit (Sangong Biotechnology,
Shanghai, People’s Republic of China) for total RNA
OncoTargets and Therapy 2016:9
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extraction. The total RNA was quantified with NanoDrop
spectrophotometer (Thermo Fisher Scientific, Waltham,
MA, USA), and 500 ng of total RNA was visualized on
1% agarose gel after electrophoresis. A miRNA library was
established with the TruSeq® miRNA Sample Prep Kit v2
(Illumina Company), with reverse transcriptase polymerase
chain reaction (RT-PCR) to enrich the library and with Qubit
kit (Thermo Fisher Scientific) to quantify miRNA libraries.
Sequencing was performed with the HiSeq2500. The data
were transformed into the FASTQ format for expression and
differential profile analysis. The results were subjected to
cluster analysis with Illumina’s software packages (SCS2.9/
RTA1.9 and Off-line Basecaller v1.9). miRNAs that were
differentially expressed, either increased or decreased, in
colorectal cancer and colorectal adenoma samples were
selected for the analysis.

Quantitative RT-PCR test and verification
of miRNA deep-sequencing results
Twelve colorectal cancer tissues as well as normal mucosa
(.10 cm away from the cancer) and 12 samples of colonic
adenoma were used for quantitative RT-PCR (qRT-PCR)
validation of the differentially expressed miRNAs revealed
by the deep sequencing. The RNA samples were derived from
patients with colorectal cancer; seven were males and five
were females, with ages ranging from 35 years to 75 years
and a median age of 65 years. These included six cases of
colorectal cancer, four cases of sigmoid cancer, and two cases
of ascending colon cancer. Additional validations were conducted by using RNA samples from 12 patients with colorectal
adenomas, eight males and four females with ages ranging
from 40 years to 73 years and a median age of 62 years. These
included seven cases of rectal polyps, four cases of sigmoid
colon polyps, and one case of ascending colon polyps.
We designed reverse transcription stem–loop primer and
specificity amplification primers, and the RNU6 qRT-PCR
was used as an internal reference for miRNA quantification.
The average Ct value of three replicates was calculated for
each sample. The Ct values of the internal reference were also
obtained three times and used for sample value corrections.
The corrected Ct values were directly plotted for differential
expression analysis. Please note that the samples were not
paired in experiments, and therefore their Ct values were unfit
for the calculation of 2-ΔΔCt (cannot appropriately subtract
the Ct value of one sample as a control group). Therefore,
direct plotting of the Ct value, which was subtracted from
the expression of the internal reference of normal, adenoma,
and cancer tissues, was used for their expressions. Oneway analysis of variance in a normal distribution and the
OncoTargets and Therapy 2016:9
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Mann–Whitney U-test equivalent, an inspection method
for nonnormal distribution or variance, were used to test all
groups studied.

Results
Differential expression of miRNAs
in different developmental stages of
colorectal cancerous tissues
To analyze the differential expression of miRNAs in different stages of colorectal cancerous tissues, miRNAs
with two-fold changes were compared for their expression patterns among adenoma, cancer, and normal mucosa
(P#0.05, expression quantity with two-fold changes).
We conducted the following comparisons (Figure 1 and
Table 1): 1) between cancerous tissue and normal mucosa
tissue; 2) between adenoma and normal mucosa; and 3)
between cancer and adenoma. Our data analysis showed
that 99 miRNAs were upregulated and 90 miRNAs were
downregulated in cancers relative to normal mucosa.
Furthermore, 114 miRNAs were found to be upregulated
and 107 downregulated in adenoma compared with normal
mucosa. Seventy miRNAs were upregulated and 27 downregulated in cancers relative to adenoma miRNAs. Among
all the upregulated miRNAs, 32 miRNAs were simultaneously upregulated in both cancer and adenoma, and nine had
significantly differential expression between adenoma and
cancer. Among all the downregulated miRNAs, 27 miRNAs
were simultaneously decreased in both adenoma and cancer,
and only two had significant differential expression between
adenoma and cancer. Nine miRNAs, increased or decreased
in both colorectal cancer and colorectal adenomas, were
chosen for further validation.

Validation of the differentially expressed
miRNAs in colorectal cancer tissues of
patients
To verify the reliability of the deep-sequencing data, we
picked 12 miRNAs that were found to be differentially
expressed by deep sequencing. The validation was conducted
using more samples of a Chinese patient population, and the
data are shown in Figures 2 and 3.
For the upregulated miRNAs (Figure 2), miR-18a-5p and
miR-21-3p were statistically significantly increased in both
adenoma and cancer tissues, compared to the normal mucosa.
miR-135b-5p, miR-17-5p, miR-182-5p, miR-200a-5p, and
miR-200c-3p were significantly upregulated in cancer compared with the normal mucosa tissues but not significantly
in adenoma relative to normal mucosa tissues. miR-183-5p
and miR-96-5p were significantly upregulated in adenoma
submit your manuscript | www.dovepress.com
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Figure 1 The results of deep sequencing of colorectal cancer miRNAs.
Notes: Three types of tissues were derived from four different patients (1–4) (A). The symbol “+” indicates that samples were collected and “-” indicates that samples were
not able to be collected. The distribution of upregulated miRNAs and their overlapping expressions in different tissues are shown in (B). The distribution of downregulated
miRNAs and their overlapping expressions in different tissues are shown in (C).
Abbreviation: miRNA, microRNA.

Table 1 miRNA markers were both upregulated and downregu
lated in both adenoma and cancer tissues
Upregulated miRNA in
both adenoma and cancer

Downregulated miRNA in
both adenoma and cancer

hsa-miR-29b-3p
hsa-miR-362-5p
hsa-miR-182-5p
chr7_9113
hsa-miR-584-5p
chrX_21021
hsa-miR-1268b
hsa-miR-552-3p
hsa-miR-21-3p
hsa-miR-96-5p
hsa-miR-17-5p
hsa-miR-20a-5p
chr21_19839
chr7_9117
hsa-miR-3182
hsa-miR-27a-5p
hsa-miR-183-5p
hsa-miR-548d-5p
hsa-miR-18a-5p
hsa-miR-23a-5p
chr17_16945
hsa-miR-135b-5p
hsa-miR-224-5p
chr15_15541
hsa-miR-1246
chr15_15204
chr15_15541_star
chr15_15204_star
chr1_1473_star
chr4_5063
hsa-miR-548d-3p

hsa-miR-135a-5p
hsa-miR-9-5p
hsa-miR-129-5p
hsa-miR-204-5p
chr20_19299
chr9_10749
hsa-miR-3195
hsa-miR-145-5p
hsa-miR-133a-3p
hsa-miR-195-3p
hsa-miR-328-3p
hsa-miR-30c-2-3p
hsa-miR-139-5p
hsa-miR-504-5p
chr17_17056
chr19_18516
chr4_5126
chr17_17055
hsa-miR-30a-5p
chr5_6947
chr6_7381
hsa-miR-30a-3p
hsa-miR-1
hsa-miR-195-5p
chr12_13116

Abbreviation: miRNA, microRNA.
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compared with normal mucosa tissues but showed no differential expression between cancer and normal mucosa.
For the downregulated miRNA (Figure 3), only miR133a-3p was significantly downregulated in both adenoma
and cancer tissues when compared with normal mucosa.
miR-204-5p, miR-125b-5p, miR-139-5p, miR-100-5p, and
miR-30a-5p were significantly downregulated in cancer
relative to normal mucosa but not significantly in adenoma
compared with normal mucosa tissues. Among these downregulated miRNAs, no miRNA showed any differential
expression either between adenoma and cancer tissues or
between cancer and normal mucosa tissues. The statistical
results are shown in Table 2.

Discussion
The use of molecular biomarkers for the early diagnosis of
colorectal cancer is an important topic of current research.2–4
Recent studies have found that miRNA plays an important
role in the pathogenesis and development of colorectal
cancer.2–4 The use of the characteristics of miRNAs, which
can be detected at early stages in the blood circulation system,
for early diagnosis of cancers has achieved very promising
results.4–7 However, due to miRNA expression variations
among different races, environments, diet styles, and so on,
the results of the detected miRNA expressions may be different. In this study, small RNA deep-sequencing experiments
were specifically conducted on samples of patients with
OncoTargets and Therapy 2016:9



1RUPDO

$GHQRPD

&DQFHU









1RUPDO

$GHQRPD

&DQFHU









1RUPDO

$GHQRPD

&DQFHU












1RUPDO

$GHQRPD

&DQFHU








1RUPDO

$GHQRPD

&DQFHU








1RUPDO

$GHQRPD

&DQFHU

∆&W PL5S518







∆&W PL5S518







∆&W PL5FS518



∆&W PL5S518





∆&W PL5S518



∆&W PL5DS518

∆&W PL5DS518 ∆&W PL5ES518
∆&W PL5S518

Screening of miRNAs for early diagnosis of colorectal cancer










1RUPDO

$GHQRPD

&DQFHU

1RUPDO

$GHQRPD

&DQFHU















1RUPDO

$GHQRPD

&DQFHU


1RUPDO

$GHQRPD

&DQFHU








1RUPDO

$GHQRPD

&DQFHU









&DQFHU



&DQFHU










1RUPDO

$GHQRPD



∆&W PL5518



∆&W PL5S518



∆&W PL5ES518





∆&W PL5DS518





∆&W PL5DS518





1RUPDO

$GHQRPD

&DQFHU

∆&W PL5S518

∆&W PL5S518



∆&W PL5S518

Figure 2 Verification results of upregulated miRNA.
Note: Figure shows the Ct value of every upregulated miRNA and its 95% confidence interval in normal mucosa, adenoma, and cancer tissues.
Abbreviations: miRNA, microRNA; Ct, cycle threshold; RNU6, cycle run six cycle.
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Figure 3 Verification results of downregulated miRNA.
Note: Figure shows the Ct value of every downregulated miRNA and its 95% confidence interval in normal mucosa, adenoma, and cancer tissues.
Abbreviations: miRNA, microRNA; Ct, cycle threshold; RNU6, cycle run six cycle.
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miRNA
Upregulated
miR-135b-5p
miR-183-5p
miR-96-5p
miR-18a-5p
miR-21-3p
miR-17-5p
miR-182-5p
miR-200a-5p
miR-200c-3p
Downregulated
miR-204-5p
miR-133a-3p
miR-145-5p
miR-145-3p
miR-1
miR-125b-5p
miR-139-5p
miR-100-5p
miR-30a-5p

P-value

Mucosa

Adenoma

Cancer

Mucosa/adenoma

Mucosa/cancer

Adenoma/cancer

17.42±2.41
21.23±3.69
18.33±2.72
16.59±1.99
24.99±2.52
21.25±7.10
23.51±3.91
22.20±6.26
23.90±4.74

17.41±1.64
27.36±2.35
21.80±2.30
18.48±1.68
17.03±3.96
17.68±4.14
25.12±3.16
22.90±3.54
21.42±3.83

14.68±2.25
21.48±2.72
19.33±2.40
14.23±1.59
16.90±5.40
12.00±2.58
19.04±2.74
13.86±3.40
13.63±3.63

0.985
0.001
0.003
0.02
0.001
0.119
0.28
0.74
0.172

0.009
0.85
0.352
0.004
0.001
0.005
0.004
0.001
0.001

0.003
0.001
0.018
0.001
0.949
0.001
0.001
0.001
0.001

12.60±5.15
9.16±3.74
14.10±4.21
11.55±4.00
19.53±4.56
9.18±3.65
13.50±3.69
13.05±3.49
11.80±2.82

16.73±3.75
14.93±2.26
16.94±4.71
14.78±4.74
19.40±3.19
11.26±7.96
17.30±6.79
14.00±4.28
12.16±4.46

16.35±4.94
15.21±3.11
12.90±7.91
15.26±7.46
21.40±4.72
16.60±6.04
21.42±3.64
20.00±2.69
17.65±2.94

0.035
0.001
0.134
0.085
0.934
0.424
0.102
0.558
0.729

0.083
0.001
0.65
0.143
0.335
0.001
0.001
0.001
0.001

0.833
0.802
0.143
0.851
0.236
0.083
0.078
0.001
0.002

Abbreviation: miRNA, microRNA.

colorectal cancer from Southeast China for studying the differential expression patterns of miRNAs among samples of
different cancer developmental stages. The objective was to
determine a standard and valuable miRNA diagnostic index
for the early detection of colorectal cancers in patients of
Southeast China.
In this study, using deep sequencing, we detected two
major types of miRNAs that are differentially expressed in
different colorectal samples: 99 upregulated miRNAs and
90 downregulated miRNAs in colorectal cancer, as well as
70 upregulated and 27 downregulated miRNAs in adenoma
tissues. The results were largely similar to previous reports2–7
and confirmed the reliability of our experiments used for
the analysis of distinct samples of Southeast China. Our
data were also cross-validated by comparison between the
deep-sequencing results and the qRT-PCR validation results.
We further identified that miR-18a-5p and miR-21-3p were
upregulated in both adenoma and cancer tissues, while miR133a-3p was downregulated in both adenoma and cancer
tissues, which offers potential early miRNA indicators for
colorectal cancer screening.
Research reported by Slattery et al8 found that overexpression of hsa-miR-18a-5p can reduce the risk of death
from colorectal cancer. A systematic review reported by
Clancy et al9 found that patients with colorectal cancers
show upregulation of circulating hsa-miR-18a-5p, which
may imply that hsa-miR-18a-5p can be used as a diagnostic
1164
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marker. Calvano Filho et al10 also found that the expression of hsa-miR-18a-5p increases in breast cancer and
this suggested a correlation may exist for other types of
cancers.
Similarly, upregulation of miR-21-3p was found not only
for colorectal cancer but also for a variety of cancers. Rotelli
et al11 found that miR-21-3p was increased in the stools of
patients with colorectal cancer and that it decreased after
surgery, which suggests that it can be used as a prognostic
factor for colorectal cancer. Other studies have found that
miR-21-3p is associated with gynecological tumors and drug
resistance.12 A few studies investigating whether it increases
in colorectal cancer and colorectal adenoma have been
conducted.12,13 Research reported by Doberstein et al14 found
that miR-21-3p increased with tumorigenesis in a variety of
tumors. In contrast, few studies have been conducted on the
role of miR-133a-3p in the pathogenesis and development
of colorectal cancer.15
In this research, differences in expression of miR-135b-5p,
miR-17-5p, miR-182-5p, miR-200a-5p, and miR-200c-3p
were statistically significant in comparisons between cancer and normal mucosa tissues, while no significance was
observed for adenoma and normal mucosa tissues. The
differences in miR-183-5p and miR-96-5p expression were
statistically significant for adenoma and normal mucosa
tissues and showed no significant differences in cancer and
normal mucosa tissues.
OncoTargets and Therapy 2016:9
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In our miRNA deep-sequencing study, the expression
patterns of miRNAs were similar in both adenoma and cancer tissues. This result might be due to several reasons. One
explanation may be the small number of patients in this study,
which requires further investigations either using larger
sample numbers for the deep sequencing or more validations using larger patient samples. Our next step will be the
verification of its value in more colorectal cancer samples.
According to the literature, variations in miRNA detection
were also associated with varying sources of patients with
cancer. There may exist miRNA expression differences
between different human races or humans with different
environmental or diet habits. One of our research objectives is
to identify such potential distinctions of miRNA expressions
in different Chinese patient populations for a more precise
medication. This study aimed to determine the links between
miRNA biomarker variation and the occurrence of colorectal
cancer in patients of Southeast China.16–22
In conclusion, this research found a number of important
miRNAs that may have diagnostic and prognostic significance in the occurrence and development of colorectal cancer. miR-18a-5p, miR-21-3p, and miR-133a-3p were found
to be up- or downregulated in both adenoma and cancer
tissues and can be used as early indicators of colorectal
cancer during screening, while the increase or decrease
of miR-135b-5p, miR-17-5p, miR-182-5p, miR-200a-5p,
miR-200c-3p, miR-183-5p, and miR-96-5p in both cancer
and adenoma tissues showed no obvious differences. Further research is necessary for determining the appropriate
screen index values that can be used for the diagnosis of
colorectal cancer.

Acknowledgments
This study was funded by the National Science Foundation
of China (numbers 30572447, 30973837, 81273944), the
Jiangsu National Science Foundation (BK20151081), the
Nanjing Science Fundation (201402041), and the Nanjing
Medical Science Foundation (YKK14140).

Disclosure
The authors report no conflicts of interest in this work.

References

1. Kumar R, Price TJ, Beeke C, et al. Colorectal cancer survival: an analysis
of patients with metastatic disease synchronous and metachronous with
the primary tumor. Clin Colorectal Cancer. 2014;13(2):87–93.

OncoTargets and Therapy 2016:9

Screening of miRNAs for early diagnosis of colorectal cancer
2. Slaby O, Svoboda M, Michalek J, Vyzula R. MicroRNAs in colorectal
cancer: translation of molecular biology into clinical application.
Mol Cancer. 2009;8:102.
3. Luo X, Burwinkel B, Tao S, Brenner H. MicroRNA signatures: novel
biomarker for colorectal cancer? Cancer Epidemiol Biomarkers Prev.
2011;20(7):1272–1286.
4. Ng EK, Chong WW, Jin H, et al. Differential expression of microRNAs
in plasma of patients with colorectal cancer: a potential marker for
colorectal cancer screening. Gut. 2009;58(10):1375–1381.
5. Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X. Plasma microRNAs
are promising novel biomarkers for early detection of colorectal cancer.
Int J Cancer. 2010;127(1):118–126.
6. Faltejskova P, Bocanek O, Sachlova M, et al. Circulating miR-17-3p,
miR-29a, miR-92a and miR-135b in serum: evidence against their
usage as biomarkers in colorectal cancer. Cancer Biomark. 2012;12(4):
199–204.
7. Schee K, Lorenz S, Worren MM, et al. Deep sequencing the microRNA
transcriptome in colorectal cancer. PLoS One. 2013;8(6):e66165.
8. Slattery ML, Herrick JS, Mullany LE, et al. An evaluation and replication of miRNAs with disease stage and colorectal cancer-specific
mortality. Int J Cancer. 2015;137(2):428–438.
9. Clancy C, Joyce MR, Kerin MJ. The use of circulating microRNAs
as diagnostic biomarkers in colorectal cancer. Cancer Biomark. 2015;
15(2):103–113.
10. Calvano Filho CM, Calvano-Mendes DC, Carvalho KC, et al. Triplenegative and luminal A breast tumors: differential expression of
miR-18a-5p, miR-17-5p, and miR-20a-5p. Tumour Biol. 2014;35(8):
7733–7741.
11. Rotelli MT, Di Lena M, Cavallini A, et al. Fecal microRNA profile in
patients with colorectal carcinoma before and after curative surgery.
Int J Colorectal Dis. 2015;30(7):891–898.
12. Karakaya C, Guzeloglu-Kayisli O, Uyar A, et al. Poor ovarian
response in women undergoing in vitro fertilization is associated with
altered microRNA expression in cumulus cells. Fertil Steril. 2015;
103(6):1469–1476. e1461–e1463.
13. Pink RC, Samuel P, Massa D, Caley DP, Brooks SA, Carter DR. The
passenger strand, miR-21-3p, plays a role in mediating cisplatin resistance in ovarian cancer cells. Gynecol Oncol. 2015;137(1):143–151.
14. Doberstein K, Bretz NP, Schirmer U, et al. miR-21-3p is a positive
regulator of L1CAM in several human carcinomas. Cancer Lett. 2014;
354(2):455–466.
15. Chung SH, Gillies M, Sugiyama Y, Zhu L, Lee SR, Shen W. Profiling
of microRNAs involved in retinal degeneration caused by selective
Muller cell ablation. PLoS One. 2015;10(3):e0118949.
16. Bertoli G, Cava C, Castiglioni I. MicroRNAs: new biomarkers for
diagnosis, prognosis, therapy prediction and therapeutic tools for breast
cancer. Theranostics. 2015;5(10):1122–1143.
17. Chang CW, Wu HC, Terry MB, Santella RM. microRNA expression in
prospectively collected blood as a potential biomarker of breast cancer
risk in the BCFR. Anticancer Res. 2015;35(7):3969–3977.
18. Della Vittoria Scarpati G, Calura E, Di Marino M, et al. Analysis of differential miRNA expression in primary tumor and stroma of colorectal
cancer patients. Biomed Res Int. 2014;2014:840921.
19. Kara M, Yumrutas O, Ozcan O, et al. Differential expressions of cancerassociated genes and their regulatory miRNAs in colorectal carcinoma.
Gene. 2015;567(1):81–86.
20. Krishnan K, Steptoe AL, Martin HC, et al. MicroRNA-182-5p targets a
network of genes involved in DNA repair. RNA. 2013;19(2):230–242.
21. Tang JF, Yu ZH, Liu T, et al. Five miRNAs as novel diagnostic biomarker candidates for primary nasopharyngeal carcinoma. Asian Pac
J Cancer Prev. 2014;15(18):7575–7581.
22. Yan X, Ding L, Li Y, et al. Identification and profiling of microRNAs from
skeletal muscle of the common carp. PLoS One. 2012;7(1):e30925.

submit your manuscript | www.dovepress.com

Dovepress

Powered by TCPDF (www.tcpdf.org)

1165

Dovepress

OncoTargets and Therapy downloaded from https://www.dovepress.com/ by 141.219.44.85 on 08-Oct-2019
For personal use only.

Wang et al

OncoTargets and Therapy

Publish your work in this journal
OncoTargets and Therapy is an international, peer-reviewed, open
access journal focusing on the pathological basis of all cancers, potential
targets for therapy and treatment protocols employed to improve the
management of cancer patients. The journal also focuses on the impact
of management programs and new therapeutic agents and protocols on

Dovepress
patient perspectives such as quality of life, adherence and satisfaction.
The manuscript management system is completely online and includes
a very quick and fair peer-review system, which is all easy to use. Visit
http://www.dovepress.com/testimonials.php to read real quotes from
published authors.

Submit your manuscript here: http://www.dovepress.com/oncotargets-and-therapy-journal

1166

Powered by TCPDF (www.tcpdf.org)

submit your manuscript | www.dovepress.com

Dovepress

OncoTargets and Therapy 2016:9

